losartan has been researched along with atorvastatin in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (25.71) | 29.6817 |
| 2010's | 20 (57.14) | 24.3611 |
| 2020's | 6 (17.14) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Liebson, PR | 1 |
| Daskalopoulou, SS; Elisaf, M; Mikhailidis, DP; Tzovaras, V | 1 |
| Ali, SA; Arayne, MS; Haroon, U; Qureshi, F; Sultana, N | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, JA | 1 |
| Georgescu, EF; Georgescu, M | 1 |
| Kirby, M; Pearmain, H; Ramsbottom, T; Usher-Smith, J | 1 |
| Duda, M; Maczewska, J; Maczewski, M | 1 |
| Lin, P; Xie, H; Xie, L; Xu, C | 1 |
| Gassman, J; Gipson, D; Greene, T; Joy, M; Pinsk, M; Savin, V; Somers, M; Trachtman, H; Vento, S; Wickman, L | 1 |
| Babaoglu, MO; Bozkurt, A; Kilicarslan, A; Sain-Guven, G; Yardimci, Y; Yasar, U | 1 |
| Drevenšek, G; Janić, M; Jerin, A; Lunder, M; Sabovič, M; Skitek, M; Ziberna, L | 1 |
| Dinarvand, B; Dinarvand, P; Farhadian, S; Jalali, A; Sanaei-Rad, P; Seyedjafari, E; Shafiee, A; Soleimani, M | 1 |
| El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A | 1 |
| Budhiraja, RD; Sharma, S; Tyagi, S | 1 |
| Drevenšek, G; Janić, M; Lunder, M; Šabovič, M; Žiberna, L | 1 |
| Černe, D; Drevenšek, G; Janić, M; Lunder, M; Marc, J; Šabovič, M | 1 |
| Cerne, D; Drevensek, G; Janic, M; Jerin, A; Lunder, M; Marc, J; Sabovic, M; Skitek, M | 1 |
| Asadikaram, G; Ebrahimi, N; Kazemi Arababadi, M; Kiani, Z; Kohan, F; Masoumi, M; Nasiri, AA; Sepehri, Z; Sheikh Fathollahi, M | 1 |
| Akershoek, JJ; Beelen, RHJ; Boekema, BKHL; Brouwer, KM; Middelkoop, E; Ulrich, MMW; Vlig, M | 1 |
| Akbari, H; Asadikaram, G; Ebrahimi, G; Ebrahimi, N; Jafari, A; Masoumi, M; Nazari-Robati, M | 1 |
| Ashcroft, JA | 1 |
| Akbari, H; Asadikaram, G; Masoumi, M; Vakili, S | 1 |
| Baranowski, A; Förster, K; Hofmann, A; Klein, A; Mattyasovszky, SG; Mickan, T; Ritz, U; Rommens, PM; Schlemmer, L; Slotina, E; Truffel, S | 1 |
| Blot, WJ; Gonzales, H; Miller, R; Muñoz, D; Munro, H; Pappalardo, S; Reynolds, C; Song, W; Tousey, P; Uzoije, P; Walkley, D; Wang, TJ; White, C | 1 |
| Attaa Bakr, N; Eid, M; Elshabrawy, Y; Saad, S | 1 |
| Bar-Klein, G; Friedman, A; Hameed, MQ; Jozwiak, S; Kaminski, RM; Klein, P; Klitgaard, H; Koepp, M; Löscher, W; Prince, DA; Rotenberg, A; Twyman, R; Vezzani, A; Wong, M | 1 |
| Glick, A; Johnson, C; Sista, V | 1 |
| Al-Mohammadi, OS; Al-Qaaneh, AM; Mustafa, SM; Obaid, WT; Rabaan, AA | 1 |
| Dong, B; Dong, S; Li, L; Liu, Q; Shen, J; Yang, K; Zhao, Y; Zhou, X; Zhu, D | 1 |
4 review(s) available for losartan and atorvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Fenofibrate; Heptanoic Acids; Humans; Losartan; Pyrroles; Uric Acid | 2005 |
Repurposed molecules for antiepileptogenesis: Missing an opportunity to prevent epilepsy?
Topics: Acetylcysteine; Animals; Anticonvulsants; Antioxidants; Atorvastatin; Brain Injuries, Traumatic; Ceftriaxone; Dibenzazepines; Drug Repositioning; Epilepsy; Epilepsy, Post-Traumatic; Erythropoietin; Fingolimod Hydrochloride; GABA Agents; Gabapentin; Humans; Immunologic Factors; Inflammation; Interleukin 1 Receptor Antagonist Protein; Isoflurane; Levetiracetam; Losartan; Neuroprotective Agents; Oxidative Stress; Pregabalin; Pyrrolidinones; Sirolimus; Stroke; Topiramate; Translational Research, Biomedical; Vigabatrin | 2020 |
4 trial(s) available for losartan and atorvastatin
| Article | Year |
|---|---|
LIFE and ARBITER.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Atenolol; Atorvastatin; Carotid Artery Diseases; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Hypertrophy, Left Ventricular; Losartan; Pravastatin; Pyrroles; Treatment Outcome | 2003 |
Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study.
Topics: Adult; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Cholagogues and Choleretics; Fatty Liver; Female; Hematologic Agents; Hepatitis; Heptanoic Acids; Humans; Losartan; Male; Middle Aged; Pentoxifylline; Pyrroles; Treatment Outcome; Ursodeoxycholic Acid | 2007 |
Novel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study design.
Topics: Adalimumab; Adolescent; Adult; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Child; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Follow-Up Studies; Galactose; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Humans; Infant; Lisinopril; Losartan; Middle Aged; Pyrroles; Treatment Outcome; Young Adult | 2011 |
Polypill for Cardiovascular Disease Prevention in an Underserved Population.
Topics: Adult; Alabama; Amlodipine; Antihypertensive Agents; Atorvastatin; Cholesterol, LDL; Community Health Centers; Drug Combinations; Female; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Medically Underserved Area; Medication Adherence; Middle Aged | 2019 |
27 other study(ies) available for losartan and atorvastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
In vitro availability of atorvastatin in presence of losartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Drug Interactions; Heptanoic Acids; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Models, Chemical; Pyrroles; Solubility; Spectrophotometry, Ultraviolet; Temperature; Time Factors | 2006 |
Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting.
Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Cost Savings; Cost-Benefit Analysis; Drug Costs; Drugs, Generic; Family Practice; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Losartan; Male; Middle Aged; Patient Satisfaction; Pyrroles; Simvastatin; Tetrazoles; Treatment Outcome | 2007 |
Evaluation of the clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a primary care setting: 2 years on.
Topics: Aged; Aged, 80 and over; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cholesterol; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Losartan; Male; Pyrroles; Retrospective Studies; Simvastatin; Tetrazoles; Therapeutic Equivalency; Treatment Outcome | 2008 |
Hypercholesterolaemia exacerbates ventricular remodelling after myocardial infarction in the rat: role of angiotensin II type 1 receptors.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Echocardiography; Heptanoic Acids; Hypercholesterolemia; Losartan; Male; Myocardial Infarction; Pyrroles; Rats; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Up-Regulation; Ventricular Dysfunction, Left; Ventricular Remodeling | 2008 |
Effects of atorvastatin and losartan on monocrotaline-induced pulmonary artery remodeling in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Atorvastatin; Base Sequence; Calcium Channels, L-Type; Disease Models, Animal; DNA Primers; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Pulmonary; Inositol 1,4,5-Trisphosphate Receptors; Losartan; Male; Monocrotaline; Pulmonary Artery; Pyrroles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases | 2010 |
Effect of atorvastatin on CYP2C9 metabolic activity as measured by the formation rate of losartan metabolite in hypercholesterolaemic patients.
Topics: Aryl Hydrocarbon Hydroxylases; Atorvastatin; Cytochrome P-450 CYP2C9; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Losartan; Male; Middle Aged; Pyrroles; Retrospective Studies | 2011 |
Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atorvastatin; Biomarkers; Blood Pressure; Coronary Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Heart; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Male; Myocardial Reperfusion Injury; Perfusion; Pyrroles; Rats; Rats, Wistar; Time Factors; Vasodilation; Vasodilator Agents | 2013 |
Novel approach to reduce postsurgical adhesions to a minimum: administration of losartan plus atorvastatin intraperitoneally.
Topics: Angiotensin Receptor Antagonists; Animals; Atorvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intraperitoneal; Losartan; Male; Mice; Plasminogen Activator Inhibitor 1; Postoperative Complications; Pyrroles; RNA, Messenger; Tissue Adhesions; Tissue Plasminogen Activator; Transforming Growth Factor beta1 | 2013 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
Effect of phosphatidylinositol 3-kinase-γ inhibitor CAY10505 in hypertension, and its associated vascular endothelium dysfunction in rats.
Topics: Acetylcholine; Animals; Aorta, Thoracic; Atorvastatin; Blood Pressure; Desoxycorticosterone; Endothelium, Vascular; Female; Glutathione; Heptanoic Acids; Hypertension; Losartan; Male; Nitrates; Nitrites; Phosphoinositide-3 Kinase Inhibitors; Pyrroles; Rats; Rats, Wistar; Thiazolidinediones | 2012 |
A low-dose atorvastatin and losartan combination directly improves aortic ring relaxation and diminishes ischaemic-reperfusion injury in isolated rat hearts.
Topics: Analysis of Variance; Animals; Aorta; Atorvastatin; Coronary Vessels; Dose-Response Relationship, Drug; Drug Therapy, Combination; Heptanoic Acids; Losartan; Male; Muscle Relaxation; Pyrroles; Rats; Rats, Wistar; Regional Blood Flow; Reperfusion Injury; Treatment Outcome | 2012 |
Treatment with low-dose atorvastatin, losartan, and their combination increases expression of vasoactive-related genes in rat aortas.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Atorvastatin; Drug Therapy, Combination; Female; Gene Expression Regulation; Heptanoic Acids; Losartan; Male; Organ Culture Techniques; Pyrroles; Random Allocation; Rats; Rats, Wistar; Treatment Outcome; Vasodilation | 2013 |
The "Rise-Peak-Fall" Pattern of Time Dependency of the Cardiovascular Pleiotropic Effects of Treatment With Low-dose Atorvastatin, Losartan, and a Combination Thereof in Rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arginine; Atorvastatin; Cardiovascular System; Carrier Proteins; CD40 Antigens; Coronary Circulation; Disease Models, Animal; Drug Therapy, Combination; Endothelium, Vascular; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Isolated Heart Preparation; Losartan; Male; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Rats, Wistar; Time Factors; Vasodilation | 2016 |
Atorvastatin, Losartan and Captopril Lead to Upregulation of TGF-β, and Downregulation of IL-6 in Coronary Artery Disease and Hypertension.
Topics: Antihypertensive Agents; Atorvastatin; Captopril; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Interleukin-6; Interleukin-8; Iran; Losartan; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha; Up-Regulation | 2016 |
Differential effects of Losartan and Atorvastatin in partial and full thickness burn wounds.
Topics: Actins; Administration, Oral; Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Burns; Cicatrix; Combined Modality Therapy; Drug Therapy, Combination; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Losartan; Muscle, Smooth; Neutrophils; Peroxidase; Skin Transplantation; Swine; Time Factors; Transplantation, Autologous; Treatment Outcome; Wound Healing | 2017 |
Atorvastatin, losartan and captopril may upregulate IL-22 in hypertension and coronary artery disease; the role of gene polymorphism.
Topics: Adult; Aged; Atorvastatin; Captopril; Case-Control Studies; Coronary Artery Disease; Female; Genotype; Humans; Hypertension; Interleukin-22; Interleukins; Iran; Losartan; Male; Middle Aged; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Up-Regulation | 2018 |
Alternatives to specific uric acid lowering treatment in gout in patients with cardiovascular disease.
Topics: Amlodipine; Angiotensin II Type 1 Receptor Blockers; Atorvastatin; Calcium Channel Blockers; Cardiovascular Diseases; Clopidogrel; Gout; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Losartan; Purinergic P2Y Receptor Antagonists; Risk Factors; Uric Acid | 2018 |
Atorvastatin and losartan may upregulate renalase activity in hypertension but not coronary artery diseases: The role of gene polymorphism.
Topics: Atorvastatin; Coronary Artery Disease; Female; Genetic Predisposition to Disease; Genotype; Humans; Hypertension; Losartan; Male; Middle Aged; Monoamine Oxidase; Polymorphism, Single Nucleotide | 2019 |
Effects of losartan and atorvastatin on the development of early posttraumatic joint stiffness in a rat model.
Topics: Animals; Atorvastatin; Disease Models, Animal; Fibrosis; Joint Capsule; Knee Injuries; Knee Joint; Losartan; Male; Rats; Rats, Sprague-Dawley | 2019 |
First-derivative synchronous spectrofluorimetric method for estimation of losartan potassium and atorvastatin in their pure forms and in tablets.
Topics: Atorvastatin; Chromatography, High Pressure Liquid; Drug Compounding; Losartan; Spectrometry, Fluorescence; Tablets | 2020 |
Oral Manifestations of Commonly Prescribed Drugs.
Topics: Albuterol; Amlodipine; Anticonvulsants; Antihypertensive Agents; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bronchodilator Agents; Deprescriptions; Drug Hypersensitivity; Fluorides; Gingival Overgrowth; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Hypoglycemic Agents; Lisinopril; Losartan; Metformin; Metoprolol; Mouth Diseases; Omeprazole; Oral Hygiene; Proton Pump Inhibitors; Simvastatin; Thyroxine; Toothpastes; Xerostomia | 2020 |
Dose-dependent atorvastatin associated with angioedema.
Topics: Aged; Amlodipine; Angioedema; Antihypertensive Agents; Atorvastatin; Calcium Channel Blockers; Female; Humans; Hypertension; Losartan | 2022 |
Effects of Long-Term Intervention with Losartan, Aspirin and Atorvastatin on Vascular Remodeling in Juvenile Spontaneously Hypertensive Rats.
Topics: Animals; Antihypertensive Agents; Aspirin; Atorvastatin; Blood Pressure; Collagen; Hypertension; Interleukin-6; Losartan; Rats; Rats, Inbred SHR; Renin; Vascular Remodeling | 2023 |